ImmunoPrecise Repays $2.75 Million In Debt, Sees $3.8 Million In Warrants Exercised

ImmunoPrecise Antibodies (TSXV: IPA) announced this morning that it has managed to remove outstanding convertible debenture debt from its balance sheet, with the company managing to pay off the remaining debt associated with the April 2018 issuance. Further, the company also announced that it has raised a total of $3.8 million from the exercise of warrants.

Originally issued with an 18 month maturity, the company managed to extend a sizable $2.75 million portion of the debt at the end of September, extending the maturity by six months. The extension at the time cost no penalty, however the interest rate was increased from 10.0% to 12.5% as part of the extension. That debt has now been paid off, via a recently completed $2.6 million convertible debenture financing as well as the receipt of $3.8 million from the exercise of warrants.

The company saw a number of warrants exercised, including 875,000 units at $1.00, 1,357,971 units at $0.70, and 1,588,500 units at $1.25.

Immunoprecise Antibodies last traded at $1.38 on the TSX Venture.


Information for this analysis was found via Sedar and ImmunoPrecise Antibodies Ltd. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Silver’s Finally Breaking the System | Keith Neumeyer – First Majestic

The Best News for Gold Was the Drop! – Peter Grandich

McEwen Copper: The Los Azules Feasibility Study

Recommended

Silver47 Completes Property-Wide Geochemical, Rock Sampling Program At Adams Plateau, Identifies Numerous Targets

Altamira Gold Identifies Presence Of Second Mineralized Porphyry Body At Cajueiro

Related News

ImmunoPrecise Begins Path to NASDAQ

This morning ImmunoPrecise Antibodies Ltd (TSXV: IPA) announced they have commenced the application process to...

Thursday, September 10, 2020, 09:45:18 AM

ImmunoPrecise Antibodies Set To Begin Trading On Nasdaq December 30

ImmunoPrecise Antibodies (TSXV: IPA) (NASDAQ: IPA) has officially been approved for listing on the Nasdaq...

Wednesday, December 23, 2020, 07:50:11 AM

ImmunoPrecise Begins Pre-Clinical Trials For SARS-CoV-2 Vaccine

ImmunoPrecise Antibodies (TSXV: IPA) and its partner LiteVax BV jointly announced this morning that they...

Friday, September 25, 2020, 08:30:35 AM

ImmunoPrecise Insider Sells $1.9 Million Worth Of Shares Over Three Days

ImmunoPrecise Antibodies Ltd (TSXV: IPA) has seen continued insider selling over the last several days....

Wednesday, September 16, 2020, 12:17:00 PM

Market Movers: Canadian Small Cap COVID-19 Stocks Take A Beating

COVID-19 related stocks are all the rage this morning, however it appears to be for...

Monday, November 9, 2020, 10:56:07 AM